Quantcast

Latest Sarcoma Stories

2011-05-27 16:00:00

INDIANAPOLIS, May 27, 2011 /PRNewswire/ -- In the press release, "Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas," issued May 19, 2011, by Eli Lilly and Company (NYSE: LLY), the following sentence has been amended to: The best overall responses were as follows: one partial response in the Ewing sarcoma tier (n=1); and no partial responses, but stable disease of 41 percent (n=9) in leiomyosarcoma; 35 percent (n=6) in synovial sarcoma; 28 percent (n=5) in Ewing family of...

2011-05-23 21:59:37

Researchers from Mount Sinai School of Medicine have discovered a protein signaling pathway that becomes hyperactivated in human sarcoma cells, suggesting that medications to inhibit this pathway may be effective in the treatment of human sarcomas. The research is published in the current issue of the journal Cancer Cell. A team of researchers led by Stuart Aaronson, MD, Jack and Jane B. Aron Professor and Chairman of the Department of Oncological Sciences at Mount Sinai School of Medicine,...

2011-05-19 07:10:00

INDIANAPOLIS, May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body. Study results demonstrated that 57 percent of patients with a soft tissue sarcoma known as adipocytic sarcoma (a rare tumor that develops from fat cells) experienced stable disease. Results from the Phase II study will be presented on Monday, June 6 at 4:15 p.m. CDT...

2011-05-12 07:00:00

SAN DIEGO, May 12, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the Company will highlight clinical development plans for its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a symposium held on Tuesday, May 24, at 1:30 p.m. China Standard Time in Taipei, Taiwan. Details about Polaris' upcoming pivotal Phase 3 clinical trial of ADI-PEG 20 in hepatocellular carcinoma (HCC) will be presented by the principal investigator, Ghassan Abou-Alfa, M.D., of...

2010-12-23 02:11:54

Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia. Now, a team of researchers, led by Aykut Ãœren, at Georgetown University Medical Center, Washington, has generated data using human cancer cell lines that suggest that ATO might also be of benefit to individuals with certain brain tumors or...

2010-12-10 00:00:49

Chief of Orthopedic Oncology in the Departments of Orthopedic Surgery and Director of the Sarcoma Divisions of the Cancer Centers, Mount Sinai Medical Center and Hackensack University Medical Center, James C. Wittig, MD ('90) profiled in the Fall 2010 Seton Hall Magazine New York, NY (PRWEB) December 8, 2010 Dr. James C. Wittig, Chief of Orthopedic Oncology in the Departments of Orthopedic Surgery and Director of the Sarcoma Divisions of the Cancer Centers, Mount Sinai Medical Center and...

2010-10-25 16:06:03

Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer. In their study, researchers at The University of Texas MD Anderson Children's Cancer Hospital in Houston found that blocking the Notch pathway in mice decreased metastases in the lungs 15-fold. The results of a series of pre-clinical studies were reported Sunday in an oral presentation at the 42nd Congress of the International Society of Pediatric...

2010-09-01 14:37:03

RNAi screening used for the first time to study Ewing's sarcoma The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute (TGen) published this month in the journal Molecular Cancer. Ewing's sarcomas are rare, but aggressive cancer lesions that occur most frequently in the bones of teenagers. They represent nearly...

2010-07-22 07:00:00

SAN DIEGO, July 22 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that the first patients have been enrolled in a Phase II clinical trial aimed at assessing the efficacy and safety of its vaccine to prevent or delay the recurrence of sarcoma. The clinical trial will enroll 126 metastatic sarcoma...

2010-07-08 18:00:00

HIGH WYCOMBE, England, July 9, 2010 /PRNewswire/ -- - In a draft appraisal the National Institute for Health and Clinical Excellence (NICE) has refused to recommend the first treatment shown to improve survival in childhood bone cancer (osteosarcoma) in more than 20 years(1,2) - Data shows Mepact(R) (mifamurtide) reduces the risk of death by almost one third when added to standard chemotherapy treatment, compared with chemotherapy alone(3) -...


Latest Sarcoma Reference Libraries

0_336928514f8c16d00d00e956be85245d
2011-02-17 15:06:48

Kaposi's sarcoma-associated herpesvirus (KSHV) one of seven currently known human cancer virus, is also the eighth human herpesvirus. Kaposi's sarcoma, caused by the virus, is common in AIDS patients, primary effusion lymphoma, and some types of multicentric Castelman's disease. Moritz Kaposi discovered the blood vessel tumor, in 1872, which would eventually be names Kaposi's sarcoma. It was originally though that KS was of Jewish and Mediterranean origins until it was found to be common...

More Articles (1 articles) »
Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related